RZLT · Rezolute, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $11.41M | $14.35M | $13.15M | $12.63M | $15.28M | $12.75M | $12.04M | $12.40M | $12.21M | $10.95M |
| SG&A | $5.95M | $9.87M | $6.67M | $4.45M | $4.74M | $4.19M | $3.15M | $3.81M | $3.70M | $3.45M |
| Total Operating Expenses | $17.37M | $24.22M | $19.82M | $17.08M | $20.02M | $16.94M | $15.19M | $16.21M | $15.91M | $14.39M |
| D&A | - | - | $8.0K | - | - | $8.0K | - | - | $10.0K | - |
| Operating Income | ($17.37M) | ($24.22M) | ($19.82M) | ($17.08M) | ($20.02M) | ($16.94M) | ($15.19M) | ($16.21M) | ($15.91M) | ($14.39M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($16.17M) | ($22.77M) | ($18.15M) | ($15.73M) | ($18.91M) | ($15.38M) | ($13.91M) | ($17.05M) | ($14.52M) | ($13.56M) |
| EPS - Basic | ($0.16) | ($0.22) | ($0.18) | ($0.22) | ($0.27) | ($0.22) | ($0.27) | ($0.34) | ($0.28) | ($0.26) |
| EPS - Diluted | ($0.16) | ($0.22) | ($0.18) | ($0.22) | ($0.27) | ($0.22) | ($0.27) | ($0.34) | ($0.28) | ($0.26) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.24M | $11.94M | $9.10M | $94.11M | $14.60M | $10.47M | $70.40M | $5.93M | $8.06M | $16.04M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.19M | $3.78M | $3.26M | $5.81M | $6.50M | $2.18M | $4.90M | $3.50M | $2.43M | $3.27M |
| Current Assets | $122.05M | $135.11M | $154.71M | $171.15M | $88.73M | $110.18M | $128.65M | $82.21M | $102.64M | $104.91M |
| Total Assets | $125.46M | $138.63M | $158.66M | $175.49M | $94.74M | $123.41M | $132.74M | $87.74M | $113.00M | $123.72M |
| Current Liabilities | $7.70M | $9.53M | $10.21M | $11.91M | $10.53M | $7.99M | $9.61M | $6.96M | $7.20M | $5.20M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.63M | $10.63M | $11.50M | $13.36M | $12.17M | $9.97M | $11.73M | $16.88M | $9.44M | $7.55M |
| Stockholders' Equity | $116.83M | $128.00M | $147.17M | $162.13M | $82.57M | $113.44M | $121.00M | $70.86M | $103.56M | $116.17M |
| Retained Earnings | ($460.95M) | ($444.78M) | ($422.01M) | ($403.86M) | ($379.47M) | ($344.82M) | ($329.44M) | ($306.47M) | ($275.51M) | ($260.99M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($17.43M) | - | - | ($16.01M) | - | - | ($10.59M) | - |
| Investing Cash Flow | - | - | ($68.49M) | - | - | ($49.41M) | - | - | ($70.0K) | - |
| Financing Cash Flow | - | - | $911.0K | - | - | $5.50M | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.9% | -16.4% | -11.4% | -9.0% | -20.0% | -12.5% | -10.5% | -19.4% | -12.9% | -11.0% |
| Return on equity | -13.8% | -17.8% | -12.3% | -9.7% | -22.9% | -13.6% | -11.5% | -24.1% | -14.0% | -11.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 15.84 | 14.18 | 15.15 | 14.37 | 8.43 | 13.79 | 13.39 | 11.82 | 14.27 | 20.18 |
| Quick ratio | 15.84 | 14.18 | 15.15 | 14.37 | 8.43 | 13.79 | 13.39 | 11.82 | 14.27 | 20.18 |
| Cash ratio | 1.46 | 1.25 | 0.89 | 7.90 | 1.39 | 1.31 | 7.33 | 0.85 | 1.12 | 3.08 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.07 | 1.08 | 1.08 | 1.08 | 1.15 | 1.09 | 1.10 | 1.24 | 1.09 | 1.06 |
| Liabilities / Assets | 0.07 | 0.08 | 0.07 | 0.08 | 0.13 | 0.08 | 0.09 | 0.19 | 0.08 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.7x | 1.9x | 6.6x | 1.9x | 2.5x | 3.0x | 1.8x | 1.8x | 0.7x | 0.9x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.3% | -41.8% | -17.0% | -12.4% | -23.5% | -6.5% | -5.6% | 5.4% | -55.7% | -18.5% |
| Net income growth (YoY) | 14.5% | -44.8% | -18.0% | -13.1% | -10.9% | -5.9% | -2.6% | -8.8% | -47.7% | -7.6% |
| EPS growth (YoY) | 40.7% | 0.0% | 18.2% | 18.5% | 20.6% | 21.4% | -3.8% | -13.3% | -47.4% | 67.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 41.5% | -21.1% | 29.7% | 34.0% | 16.5% | 9.5% | 4.2% | -44.3% | -32.4% | -22.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Rezolute against the 5 most active filers in the same SIC group.